PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials Chenxi LiMeiqi HaoWenxiong Zhang Review Article 02 February 2023 Pages: 203 - 217
Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions Jan H. BeumerBenjamin C. KennardAllison Dunn Original Article 23 February 2023 Pages: 219 - 230
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients Melanie DonnetteLoic OsannoRaphaëlle Fanciullino Original Article 01 March 2023 Pages: 231 - 238
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations Georgina Meneses-LorenteElena GueriniNassim Djebli Original Article Open access 08 March 2023 Pages: 239 - 246
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer Loek A. W. de JongMarie LambertPetronella B. Ottevanger Original Article Open access 09 March 2023 Pages: 247 - 256
Assay performance and stability of uracil and dihydrouracil in clinical practice Jonathan E. KnikmanHilde RosingJos H. Beijnen Original Article 11 March 2023 Pages: 257 - 266
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants Vassilios AslanisRobert J. SlackFredrik Zetterberg Original Article Open access 13 March 2023 Pages: 267 - 280
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies Danielle ShaferAmanda B. KaganSteven Grant Clinical Trial Report 02 March 2023 Pages: 281 - 290